ER-100, RTR242 and RLS-1496 Put Three Aging Mechanisms Into Early Human Tests

The claim that a drug can reverse human aging is far ahead of the clinical evidence. Yet three experimental programs—ER-100, RTR242 and RLS-1496—deserve attention for a more defensible reason: each has moved a different mechanism associated with aging into human testing. Their trials are not interchangeable, and none is designed to demonstrate longer life. Together, however, they show how geroscience is becoming a set of testable therapeutic programs rather than one sweeping promise.

ER-100 tests controlled epigenetic restoration in the eye

Life Biosciences' ER-100 is an investigational gene therapy built around partial epigenetic reprogramming. It uses modified adeno-associated viral vectors to deliver OCT4, SOX2 and KLF4—three transcription factors collectively known as OSK—to retinal cells. The objective is to restore more youthful gene-expression and DNA-methylation patterns without fully erasing cellular identity. Full reprogramming can push mature cells toward pluripotency, a state that would be unacceptable inside a patient. Partial, time-controlled expression is intended to seek some rejuvenating effects while limiting that risk.

The FDA authorized a first-in-human Phase 1 study in people with open-angle glaucoma or non-arteritic anterior ischemic optic neuropathy. The ClinicalTrials.gov record describes intravitreal administration to one eye, followed by oral doxycycline for eight weeks to activate OSK expression. Dose escalation begins in glaucoma, after which a selected dose can move into the NAION cohort. Safety, tolerability and immune responses are central endpoints, with visual assessments providing exploratory evidence of potential benefit. Participants are followed for years because delayed effects matter in gene-therapy development.

This is not a trial of generalized age reversal. The eye is a contained organ, the intervention is locally delivered, and the enrolled patients have serious optic-nerve diseases. Even a favorable vision result would first support a treatment hypothesis for damaged retinal ganglion cells—not the conclusion that a person's body has become younger.

RTR242 targets lysosomes and autophagic flux

Retro Biosciences' RTR242 is an oral small molecule designed to improve lysosomal function and increase autophagic flux. Autophagy is the process by which cells identify, break down and recycle damaged proteins, organelles and other material. Lysosomes are essential to the final disposal and recycling steps. Both systems can become less efficient with age and in neurodegenerative disease, making them attractive therapeutic targets.

The Australian trial registry lists a randomized, double-blind, placebo-controlled Phase 1 study in healthy adults. Its single-ascending-dose, food-effect and multiple-ascending-dose cohorts are designed to establish safety, tolerability and pharmacokinetics. Retro says RTR242 entered the clinic in 2025 and lists Alzheimer's disease as the program's opening indication. The Phase 1 design does not test whether the compound slows dementia, improves cognition or lengthens life. It establishes whether exposures suitable for later patient studies can be reached without unacceptable toxicity.

That boundary is important. Improving a cellular recycling pathway is biologically plausible; proving a disease-modifying effect requires controlled patient data. Autophagy is also a regulated system rather than a universally beneficial dial. More activity is not automatically better in every tissue, disease state or dose range.

RLS-1496 brings senotherapeutics into diseased skin

Rubedo Life Sciences' RLS-1496 is a topical GPX4-modulating senotherapeutic intended to target pathological senescent and stressed cells. Senescent cells stop dividing and can release inflammatory signals, but senescence also contributes to processes such as wound repair and tumor suppression. Rubedo's stated strategy is selective modulation rather than indiscriminate clearance.

A registered open-label Phase 1b/2a study is evaluating 1 percent RLS-1496 cream in adults with actinic keratoses, precancerous lesions linked to cumulative ultraviolet exposure. Participants treat a defined area on one forearm for 28 days while the opposite forearm remains untreated. The study measures adverse events, local tolerability, lesion clearance, target engagement and senescence-related biomarkers.

Rubedo reported that among the first 18 evaluated participants, lesion counts fell 46 percent on treated arms at four weeks, compared with 11 percent on untreated arms, with what the company characterized as minimal irritation. That is an intriguing preliminary signal, not a definitive efficacy result. The study is small and open-label, the control is untreated rather than vehicle-treated, and the figures were company-reported rather than results posted in the registry or a peer-reviewed full paper. It also concerns localized skin disease, not systemic aging.

What these programs can actually establish

ER-100, RTR242 and RLS-1496 do not form an anti-aging drug cabinet. They are early clinical experiments aimed at specific diseases through three different biological systems. The meaningful milestones now are safety, target engagement, dose selection and credible disease outcomes.

If those milestones are met, later trials can ask whether the interventions preserve function or modify disease. Only substantially longer and broader evidence could address effects on healthspan, multiple organ systems or survival. For now, the advance is not that human aging has been reversed. It is that prominent ideas in aging biology are finally being subjected to clinical tests capable of proving them wrong.